{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:07:25Z","timestamp":1791086845003,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,4,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To perform a phase II study of the farnesyltransferase inhibitor R115777 (Zarnestra; Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ) in patients with myelodysplastic syndrome (MDS), using doses recommended in a phase I study in relapsed\/refractory leukemia. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with MDS were treated with R115777 at doses of 600 mg orally (PO) bid in cycles of 4 weeks of therapy followed by a 2-week rest period. Dose reduction rules for toxicity were applied. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Twenty-seven of the 28 patients treated were assessable. Three patients responded (complete remission, n = 2; partial remission, n = 1). Responders included two patients with refractory anemia with excess blasts and one patient with refractory anemia with excess blasts in transformation. Two of the responders had a diploid karyotype and one had multiple cytogenetic abnormalities including monosomy 5 and 7. The starting dose of 600 mg PO bid resulted in side effects (myelosuppression, fatigue, neurotoxicity, rash, or leg pain) necessitating dose reduction (n = 4) or discontinuation of therapy (n = 7) in 11 (41%) of 27 patients during the induction period (12 weeks). Lower doses of 300 mg PO bid were well tolerated. All responses occurred in patients who had been reduced to this dose level during the initial two cycles. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> This study suggests that R115777 has modest activity in MDS patients, but that, in this patient population, 4 weeks of daily doses of 600 mg PO bid is not tolerated. Further exploration of the optimal dose\/schedule and correlation with biologic end points are warranted. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2004.08.082","type":"journal-article","created":{"date-parts":[[2004,3,29]],"date-time":"2004-03-29T23:28:11Z","timestamp":1080602891000},"page":"1287-1292","source":"Crossref","is-referenced-by-count":111,"title":["Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome"],"prefix":"10.1200","volume":"22","author":[{"given":"Razelle","family":"Kurzrock","sequence":"first","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu H.","family":"Estey","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.","family":"Faderl","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Ryback","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Thibault","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"De Porre","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Departments of Bioimmunotherapy, Hematopathology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, and Beerse, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402107"},{"key":"R2","unstructured":"Ganser A, Hoelzer D: Clinical use of hematopoietic growth factor in the myelodysplastic syndromes. Semin Hematol 33:186,1996-195,"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.11.4275.4275"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Vergilio JA, Bagg A: Myelodysplastic syndromes. Contemporary biologic concepts and emerging diagnostic approaches. Am J Clin Pathol 119:S58,2003-S77,  (suppl)","DOI":"10.1309\/T8DFXEXMYLHW51DG"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb08475.x"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2819"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.220"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.1071"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0004(93)90072-U"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.7.9.8330683"},{"key":"R13","unstructured":"Rodenhuis S: ras and human tumors. Semin Cancer Biol 3:241,1992-247,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.6.1855"},{"key":"R15","unstructured":"End DW, Smets G, Todd AV, et al: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131,2001-137,"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003469200"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006213200"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3361"},{"key":"R19","unstructured":"Cunningham D, De Gramont A, Schiethaurer W, et al: Randomized double-blind, placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra\u2122) in advanced colorectal cancer. Proc Am Soc Clin Oncol 21:126a,2002,  (abstr 502)"},{"key":"R20","unstructured":"Van Cutsem E, Karasek P, Oettle H, et al: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer. Proc Am Soc Clin Oncol 21:130a,2002,  (abstr 517)"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3631"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3359"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1973"},{"key":"R25","unstructured":"Charvat S, Duchesne M, Parvaz P, et al: The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor. Anticancer Res 19:557,1999-561,"},{"key":"R26","unstructured":"Rak J, Mitsuhashi Y, Bayko K, et al: Mutant ras oncogenes upregulate VEGF\/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575,1995-4580,"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.0.CO;2-5"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2240"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.08.082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:24:37Z","timestamp":1653510277000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.08.082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,4,1]]}},"alternative-id":["10.1200\/JCO.2004.08.082"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.08.082","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,1]]}}}